NCT05413655RecruitingPhase 2
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 26 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 14 Mar 2022
- Start date
- 8 Aug 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Excelsior
- Diseases
- Alzheimer disease
- NCT number
- NCT05413655
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 8 Aug 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having substantial concomitant cerebrovascular disease (defined by a history of a stroke
- / intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.
Other illness
- Having other causes of dementia.
- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
- Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement:
- Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension.
- Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV.
- Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
- Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism.
- Unstable/Uncontrolled major depression.
- Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis).
- Significant pulmonary disease predisposing to hypoxia.
- Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease)
- Any other psychiatric disorders such as schizophrenia, or mental retardation.
- Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders \[DSM-V\] or in the opinion of the investigator)
- Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole.
Other
- Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- Hachinski Ischemic Score \> 4
- Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
Who the study is looking for
- Aged 50-80 years.
- Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011)
- Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-26.
- Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of 1.
- Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria:
- AST, ALT level ≦ upper limit of normal
- Creatine Kinase (CK) concentration more than 3 times upper limit of normal
- Serum creatinine level ≦ upper limit of normal
- HbA1c more than 8.0
- Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities.
- Cognitive deficits caused impairment in social or occupational function.
- Disease progression with gradual and continued decline from a previous level of functioning.
- Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control.
- Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study.
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.